PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01212757 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

488

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Apremilast 20mg
DRUG: Apremilast 30mg
DRUG: Placebo + 20 mg Apremilast
DRUG: Placebo + 30 mg Apremilast

Sponsor

Amgen